There is tremendous potential for innovation in Ophthalmology.
The company’s current therapeutic focus is on glaucoma, a serious disease
that affects 1%-2% of the U.S. population and over 60 million people worldwide.
Glaucoma represents 41% of a $4.6 Billion US business (2007) and is the largest
market in ophthalmic pharmaceuticals. The first generation prostaglandin
agonists are the leading class of products in this market, with the global
market leader Xalatan® (latanoprost; Pfizer) earning over $1.7 Billion in
annual revenues (2008).